Compare SEE & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEE | BLTE |
|---|---|---|
| Founded | 1960 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.5B |
| IPO Year | 1996 | 2021 |
| Metric | SEE | BLTE |
|---|---|---|
| Price | $42.15 | $171.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $43.50 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 3.0M | 148.5K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 89.50 | N/A |
| EPS | ★ 3.43 | N/A |
| Revenue | ★ $5,359,800,000.00 | N/A |
| Revenue This Year | $1.93 | N/A |
| Revenue Next Year | $2.27 | $492.11 |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.56 | $53.60 |
| 52 Week High | $44.27 | $200.00 |
| Indicator | SEE | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 65.73 | 55.03 |
| Support Level | $41.79 | $167.80 |
| Resistance Level | $42.21 | $174.78 |
| Average True Range (ATR) | 0.08 | 8.50 |
| MACD | 0.02 | 2.11 |
| Stochastic Oscillator | 100.00 | 71.15 |
Sealed Air Corp is a provider of packaging solutions that integrate sustainable, high-performance materials, automation, equipment, and services. The company designs, manufactures, and delivers packaging solutions that preserve food, protect goods, and automate packaging processes. It delivers its packaging solutions to an array of end markets including fresh proteins, foods, fluids and liquids, medical and life science, e-commerce retail, logistics and omnichannel fulfillment operations, and industrials. It has two reportable segments, Food and Protective. The company generates majority of its revenue from the food segment.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.